- Citation
- Lee K., Ambler C., Anderson D., Boscoe B., Bree A., Brodfuehrer J., Chang J., Choi C., Chung S., Curran K., Day J., Dehnhardt C., Dower K., Drozda S., Frisbie R., Gavrin L., Goldberg J., Han S., Hegen M., Hepworth D., Hope H., Kamtekar S., Kilty I., Lee A., Lin L., Lovering F., Lowe M., Mathias J., Morgan H., Murphy E., Papaioannou N., Patny A., Pierce B., Rao V., Saiah E., Samardjiev I., Samas B., Shen M., Shin J., Soutter H., Strohbach J., Symanowicz P., Thomason J., Trzupek J., Vargas R., Vincent F., Yan J., Zapf C., Wright S.: Discovery of Clinical Candidate 1-{[(2
<i>S</i>
,3
<i>S</i>
,4
<i>S</i>
)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. Journal of Medicinal Chemistry, Volume 60 (13), 2017
- Authors
- Katherine L. Lee, Catherine M. Ambler, David R. Anderson, Brian P. Boscoe, Andrea G. Bree, Joanne I. Brodfuehrer, Jeanne S. Chang, Chulho Choi, Seungwon Chung, Kevin J. Curran, Jacqueline E. Day, Christoph M. Dehnhardt, Ken Dower, Susan E. Drozda, Richard K. Frisbie, Lori K. Gavrin, Joel A. Goldberg, Seungil Han, Martin Hegen, David Hepworth, Heidi R. Hope, Satwik Kamtekar, Iain C. Kilty, Arthur Lee, Lih-Ling Lin, Frank E. Lovering, Michael D. Lowe, John P. Mathias, Heidi M. Morgan, Elizabeth A. Murphy, Nikolaos Papaioannou, Akshay Patny, Betsy S. Pierce, Vikram R. Rao, Eddine Saiah, Ivan J. Samardjiev, Brian M. Samas, Marina W. H. Shen, Julia H. Shin, Holly H. Soutter, Joseph W. Strohbach, Peter T. Symanowicz, Jennifer R. Thomason, John D. Trzupek, Richard Vargas, Fabien Vincent, Jiangli Yan, Christoph W. Zapf, Stephen W. Wright
- Journal
- Journal of Medicinal Chemistry
- Year
- 2017
- Machine-readable
- REST APIRDF